Luminex Posts 1 Percent Q3 Revenue Growth, Lowers Guidance Citing Reimbursement Issues | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its third quarter revenues grew 1 percent over the third quarter of 2012, but the Austin, Texas-based molecular diagnostics company lowered its revenue guidance for the year, citing US reimbursement issues.

Luminex's total revenues for the three months ended Sept. 30 were $50.8 million, compared to $50 million in the third quarter of 2012. The firm fell short of analysts' consensus expectations for revenue of $54.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.